Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $211 | $129 | $0 | $0 |
| % Growth | 63.4% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $211 | $129 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $125 | $100 | $67 | $36 |
| G&A Expenses | $38 | $32 | $31 | $15 |
| SG&A Expenses | $38 | $32 | $31 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $164 | $132 | $97 | $51 |
| Operating Income | $47 | -$3 | -$97 | -$51 |
| % Margin | 22.3% | -2.5% | – | – |
| Other Income/Exp. Net | $19 | $15 | $3 | -$0 |
| Pre-Tax Income | $66 | $12 | -$95 | -$51 |
| Tax Expense | $1 | $19 | $0 | $0 |
| Net Income | $66 | -$7 | -$95 | -$51 |
| % Margin | 31.1% | -5.2% | – | – |
| EPS | 1.76 | -0.2 | -2.79 | -1.6 |
| % Growth | 980% | 92.8% | -74.4% | – |
| EPS Diluted | 1.68 | -0.2 | -2.79 | -1.6 |
| Weighted Avg Shares Out | 37 | 33 | 31 | 31 |
| Weighted Avg Shares Out Dil | 39 | 33 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19 | $15 | $3 | $0 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $4 | $3 | $2 | $1 |
| EBITDA | $51 | -$0 | -$95 | -$50 |
| % Margin | 24.1% | -0.2% | – | – |